An observational study in Sarcopenia, sponsored by Namik Kemal University. Terminated at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Namik Kemal University · Observational
Due to an overly detailed methodology and strict inclusion/exclusion criteria, patient recruitment was insufficient (poor accrual), leading to early termination of the study.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Sarcopenia with a site in Turkey — 36 open to participants now, 43 under way, none of them phase 3. Sarcopenia · Turkey.
Among the 131 studies in Sarcopenia with a site in Turkey, this one is the 95th largest by enrollment of the 97 observational ones that give a count, is one of 25 that started in 2025, is one of 97 observational ones, and was the 33rd registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →36 of the 131 studies in Sarcopenia with a site in Turkey are open now. Recruiting first, the newest first:
Marmara University · Sites in Turkey
Ages 50–75
Izmir Democracy University · Sites in Turkey
Ages 6–18 · Healthy volunteers
Tarsus University · Sites in Turkey
Ages 65–80
Van Training and Research Hospital · Sites in Turkey
Ages 60+
Istanbul Saglik Bilimleri University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 25 started in 2025.
This study's enrollment of 20 is below the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 40 across the 34 interventional studies, 100 across the 97 observational. Of the 76 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 131 have an industry lead sponsor. The 10 most frequent:
Namik Kemal University is the lead sponsor of 62 studies on the registry; 18 are open to participants now.
Namik Kemal University has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
18 of the studies in Sarcopenia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07813702MERT UYSALURINARY INCONTINENCE AND GERIATRIC SYNDROMES | 2026-11 |
| NCT07858864Istanbul Saglik Bilimleri UniversityGLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | 2026-11-30 |
| NCT07842731Atılım UniversityInvestigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters | 2026-12-10 |
| NCT06749340Bahçeşehir UniversityExamining the Effects of Different Resistive Exercise Programs in Individuals With Compensated Liver Cirrhosis | 2026-12-23 |
| NCT07357662Tarsus UniversityEffects of Rehabilitative Exergame Training on Foot Muscle Activity, Balance, and Mobility in Older Adults | 2026-12-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 131 studies in Sarcopenia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In order to prevent sarcopenia in intensive care patients and to guide nutritional therapy, evaluation of muscle thickness with ultrasonography is a modern, simple and non-invasive procedure routinely performed by Anesthesiology and Reanimation specialists. Sarcopenia in intensive care patients has been demonstrated in many studies. It has been studied that routine examination of changes in rectus femoris muscle thickness by ultrasonography is a predictor of sarcopenia. However, the muscles in the neck region, such as the sternocleidomastoid muscle, which are easy to examine, have not been studied very well. There is no study in the literature with the sternocleidomastoid muscle. For this reason, we decided to examine the relationship of sternocleidomastoid muscle thickness with patient characteristics, treatments, feeding route and type, feeding time, length of stay in intensive care unit, as in routine measurements of rectus femoris muscle thickness by ultrasonography.
Sarcopenia is an important clinical condition, characterized by a decrease in muscle mass and function that increases with age, especially in elderly patients. Studies have shown that sarcopenic patients have higher morbidity and mortality rates than non-sarcopenic patients. Along with the increased risk of muscle wasting in intensive care patients, there is an increase in both hospital mortality rates and the frequency of post-hospital mobilization problems.
Intensive care patients are a group of patients who are very prone to protein-energy malnutrition, and this leads to complications such as nosocomial infection and multiple organ failure, leading to prolongation of the stay in the intensive care unit, as well as an increase in morbidity and mortality. Therefore, nutritional support is a routine requirement of intensive care treatment and has a vital role in the prevention and treatment of nutritional deficiencies in intensive care patients.
The first point that should be evaluated in terms of the follow-up of a patient on whom nutritional support is maintained is to know for what reason, when, and what kind of treatment is planned in terms of quality and quantity. This is a starting point for monitoring. Knowing the patient's clinical and laboratory values when nutritional therapy is initiated allows the evaluation of how these data have changed during follow-up. The purpose of assessment of nutritional status is to identify the type and degree of malnutrition in order to make a rational treatment approach. However, there is no test that is both sensitive and specific to determine malnutrition in intensive care patients.
Patients who are expected to be followed up in the intensive care unit for at least 1 week in a tertiary university research and education hospital based 11 bed ICU
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography
Diagnostic Test: Muscle thickness measurement
Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
Muscle thickness
Rectus femoris and Sternocleidomastoideus muscle thickness change when compared to the value measured at admission to the intensive care unit.
Time frame: 1 week
Nutrition regime
Nutrition regimes, calorie and protein intake during admission will be saved.
Time frame: 1week
Nutrition Scores
NRS 2002, NUTRIC scores will be calculated in admission
Time frame: Day 1
Plan to share: Undecided
Ran from Sep 2025 to primary completion in Sep 2026, 12 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Feb 2026 → Sep 2026 and completion Feb 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Due to an overly detailed methodology and strict inclusion/exclusion criteria, patient recruitment was insufficient (poor accrual), leading to early termination of the study.
Due to an overly detailed methodology and strict inclusion/exclusion criteria, patient recruitment was insufficient (poor accrual), leading to early termination of the study.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Namik Kemal University